This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mixed Bag for Pfizer

Pfizer (PFE) said the Food and Drug Administration rejected its application for Oporia, an experimental treatment for osteoporosis.

In a terse, two-sentence announcement, Pfizer said it will discuss its application with the agency and consider "various possible courses of action." The FDA's rejection of Oporia, known by its scientific name lasofoxifene, was a setback for a drug that Pfizer had hoped would have multiple uses.

Pfizer filed its osteoporosis application with the agency 13 months ago. In December, it asked the FDA to approve the drug as a treatment for vaginal atrophy. A Pfizer spokeswoman said the FDA hasn't commented on the vaginal atrophy application.

The news helped send Pfizer's stock down 33 cents, or 1.3%, to $26.01 in early afternoon trading. Shares of Pfizer's partner, Ligand Pharmaceuticals, (LGND) fell 79 cents, or 9%, to $8.01.

Pfizer's collaboration with Ligand, which now trades as a "pink sheet" stock, calls for Ligand to receive certain royalty payments during the drug's development. Ligand will get other payments if the drug is approved, and it will receive additional royalties equal to 6% of worldwide sales for any approved use of the drug.

San Diego-based Ligand, which has development deals with several Big Pharma companies, said Monday night that it's now the subject of a formal investigation by the Securities and Exchange Commission regarding the companies restatement of earnings for 2002 and 2003, each quarter of 2003 and the first three quarters of 2004.

"These matters have been the subject of an informal SEC inquiry," Ligand said in a press release issued Monday about six hours after markets had closed. "Ligand has been fully cooperating with the SEC and will continue to do so."

Ligand was delisted from Nasdaq last week. The company is seeking reinstatement, saying that it hopes to be in compliance with all SEC financial report-filing guidelines within 60 days.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs